Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesHelix BioPharma Corp.

Helix BioPharma Corp.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.92 CAD -0.10 ( 9.80%)
Last update at 2026-11-03T20:45:00Z
VOLUME
15
Market Cap
148.17M

Momentum Score

…

Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.90
Low
0.98
High
52 Week Price Range
0.78
Low
5.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Helix BioPharma Corp. is a Canadian biotechnology company with limited publicly available information about its current pipeline and operations. It appears positioned in oncology and immunotherapy development where long-term growth drivers include successful clinical trial results, regulatory approvals, and potential partnerships or licensing that could support commercialization.
The most important investment risks are clinical and regulatory failure, high financing and dilution risk for a small-cap biotech, limited liquidity, and operational uncertainty.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.02
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.02
ROE
-54.70%
Net Debt
0.27M
ROCE
-33.51%
Diluted EPS TTM
-0.06

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Income before tax -5.23M -9.40M -6.29M -6.56M -9.57M
Minority interest - - - - 0.00M
Net income -5.21M -9.26M -6.29M -6.58M -7.99M
Selling general administrative 1.84M 3.26M 1.04M 0.59M 3.25M
Gross profit -0.01M -0.01M - - -
Reconciled depreciation - 0.01M 0.01M 0.01M 0.20M
Ebit -5.22M -9.39M - -6.54M -9.61M
Ebitda -5.21M -9.38M - -6.53M -9.41M
Depreciation and amortization 0.01M 0.01M - 0.01M 0.20M
Operating income -5.42M -9.37M -6.33M -6.54M -9.61M
Other operating expenses 5.42M 9.37M - 6.04M 9.13M
Interest expense 0.01M 0.01M 0.01M 0.02M 0.01M
Interest income 0.13M 0.03M 0.03M 0.02M 0.04M
Net interest income - 0.02M 0.03M -0.01M -0.35M
Extraordinary items - - - 0.00M 1.54M
Income tax expense -0.03M -0.13M - 0.02M -1.59M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 5.42M 9.36M 6.33M 6.04M 9.13M
Cost of revenue 0.01M 0.01M - - -
Total other income expense net 0.19M -0.03M 0.00M -0.03M 0.04M
Discontinued operations - - - - 1.54M
Net income from continuing ops - -9.26M -6.29M -6.56M -9.57M
Net income applicable to common shares -5.21M -9.26M -6.29M -6.56M -8.04M
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Total assets 18.80M 1.49M 1.03M 3.73M 4.07M
Intangible assets 18.39M - - - -
Other current assets 0.22M - - -0.00M 0.00M
Total liab 3.22M 1.58M 1.87M 3.41M 5.46M
Total stockholder equity 15.59M -0.09M -0.84M 0.32M -1.39M
Other current liab 2.88M - 1.00M 0.34M 0.38M
Common stock 179.29M - 152.07M 147.51M 139.66M
Capital stock - 158.57M 152.07M 147.51M 139.66M
Retained earnings -215.88M -210.67M -197.05M -195.12M -188.55M
Other assets - - - -0.00M -
Cash 0.07M 1.08M 0.81M 3.25M 3.56M
Total current liabilities 3.22M 1.58M 1.87M 3.41M 3.87M
Net debt 0.27M - - -0.78M 0.05M
Short term debt 0.34M - 0.00M 2.47M 2.03M
Short long term debt - - - 2.47M 2.03M
Short long term debt total 0.34M - - 2.47M 3.61M
Other stockholder equity 48.30M - - 47.92M 47.50M
Property plant equipment 0.00M - 0.03M 0.04M 0.05M
Total current assets 0.41M 1.46M 1.00M 3.69M 4.02M
Net tangible assets - - - 0.32M -1.39M
Net receivables 0.12M - 0.06M 0.28M 0.35M
Long term debt - - - 0.00M 1.58M
Inventory - - - 0.16M -
Accounts payable - 0.85M 0.49M 0.60M 1.47M
Accumulated other comprehensive income 3.87M - - - -
Non currrent assets other - - - 0.00M -
Non current assets total 18.39M 0.03M 0.03M 0.04M 0.05M
Long term debt total 0.00M - 0.00M 0.00M 1.58M
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Investments - -0.01M -0.01M 0.00M 2.02M
Change to liabilities - - - -0.87M 0.05M
Total cashflows from investing activities 0.02M -0.01M -0.01M 0.00M 2.02M
Net borrowings - 0.00M - - 3.00M
Total cash from financing activities 2.80M 5.51M 3.09M 6.21M 6.56M
Change to operating activities - - - -0.10M 0.07M
Net income -5.21M -9.26M -6.29M -6.56M -8.04M
Change in cash -1.02M 0.27M -2.44M -0.31M -0.67M
Begin period cash flow 1.08M 0.81M 3.25M 3.56M 4.24M
End period cash flow 0.07M 1.08M 0.81M 3.25M 3.56M
Total cash from operating activities -3.83M -5.22M -5.53M -6.51M -9.30M
Issuance of capital stock - 5.51M 4.15M 2.99M 3.56M
Depreciation 0.01M 0.01M 0.01M 0.01M 0.20M
Other cashflows from investing activities 0.02M - 0.01M 0.00M 2.02M
Change to account receivables -0.07M 0.01M 0.22M 0.07M -0.17M
Sale purchase of stock 2.80M 5.51M 4.15M 6.21M 3.56M
Other cashflows from financing activities - -0.01M 1.00M 3.21M 3.16M
Change to netincome - - - 0.93M -1.41M
Capital expenditures 0.00M 0.01M 0.01M 0.00M 0.00M
Change in working capital 1.33M 0.48M 0.19M -0.89M -0.05M
Stock based compensation - 3.52M 0.57M 0.42M 0.66M
Other non cash items 0.03M 0.03M - 0.51M -2.07M
Free cash flow -3.83M -5.23M -5.54M -6.51M -9.30M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HBP
Helix BioPharma Corp.		 -0.10
9.80%		 0.92 - 3.87 4263.36 9.74 4422.35 -6.36
EPRX
Eupraxia Pharmaceuticals Inc		 0.19
1.97%		 9.84 - - - 8.45 - -3.88
FRX
Fennec Pharmaceuticals Inc		 0.20
1.35%		 14.99 - 21.01 6.95 6.35 4.25 20.27
MSCL
Satellos Bioscience Inc.		 -
-%		 9.00 - - - 5.85 - 6.47
SVA
Sernova Corp		 -0.01
4.35%		 0.11 - - 65.86 24.15 36.69 -11.27

Profile*

Helix BioPharma Corp.

Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.

1055 West Georgia Street, Vancouver, BC, Canada, V6E 3P3

905-841-2300

https://www.helixbiopharma.com

7

Name Title Year Born
Mr. Hatem Kawar M.B.A., MBA, P.Eng, P.Eng. Chief Financial Officer 1959
Dr. Gabrielle M. Siegers M.A., Ph.D. Head of R&D NA
Ms. Namrata Malhotra Corp. Sec. NA
Mr. Jacek Antas Chairman & CEO NA
Mr. Praveen Kumar Varshney F.C.A., FCA, FCPA, LLB CFO & Corporate Secretary 1966
Dr. Srikanth Sola Chief Strategy Officer NA
Dr. Christof Boehler Chief Business Development Officer NA
Mr. Jacek Antas Chairman, CEO & Corporate Secretary NA
Mr. Rohit Babbar C.A., CPA Chief Financial Officer NA
Ms. Veronika Kandziora Chief Operating Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ORE
CAD 2.77
+8.86%
APM
CAD 4.95
+8.08%
NUAG
CAD 7.37
+8.06%
BZ
CAD 4.03
+8.04%
AYA
CAD 34.85
+7.96%
HUT
CAD 73.56
-17.26%
PHX
CAD 11.13
-12.22%
IVN
CAD 7.93
-10.70%
EFN
CAD 20.09
-10.39%
OBE
CAD 13.62
-6.71%

Equity Sectors*

  • Basic Materials

    +3.73%

  • Communication Services

    +1.16%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.14%

  • Energy

    -1.87%

  • Financial Services

    +1.53%

  • Healthcare

    +1.50%

  • Industrials

    +0.03%

  • Real Estate

    +0.71%

  • Technology

    +0.40%

  • Utilities

    +0.35%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…